The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.

Wave Life Sciences (WVE) stock rises on plans to file for FDA accelerated approval of WVE-N531 in 2026, targeting Duchenne muscular dystrophy. Read more here.

Ottawa has imposed 25 per cent counter-tariffs on American goods as part of Canada's retaliation to U.S. President Donald Trump's trade war. Trump followed through on a months-long threat on ...

The weather event was upgraded to a category two system overnight and on Tuesday did a U-turn about 600km off Brisbane ... The BOM is warning high waves and falls of up to 200mm will batter ...

By Gail Mitchell Ty Baisden, co-founder of the creative/business partnership company COLTURE, is announcing the launch of the firm’s Empower U Grant, dedicated to uplifting and supporting women ...

Maite joined the AS USA in 2021, bringing her experience as a research analyst investigating illegal logging to the team. Maite’s interest in politics propelled her to pursue a degree in ...

U.S.A.I.D. Advertisement Supported by Here are some of the 5,800 contracts the Trump administration formally canceled this week in a wave of terse emails. By Stephanie Nolen Stephanie Nolen covers ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...